In our study, the broad-spectrum methyltransferase inhibitor Sinefungin, previously shown to inhibit the MNX1-drived leukemogenesis5, was able to downregulate MNX1-induced PBX1 expression, reinforcing the potential of targeting histone methylation in t(7;12) AML. This evidence concerns the gene MNX1 and acute myeloid leukemia.